Litcius/Paper detail

Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study

Joseph J. Eron, Susan J. Little, Gordon Crofoot, Paul Cook, Peter Ruane, Dushyantha Jayaweera, Laurie A. VanderVeen, Edwin DeJesus, Yanan Zheng, Anthony Mills, Hailin Huang, Sarah Waldman, Moti Ramgopal, Linda Gorgos, Sean E Collins, Jared M. Baeten, Marina Caskey

2024The Lancet HIV45 citationsDOIOpen Access PDF

Topics & Concepts

RegimenMedicineAdverse effectClinical endpointIncidence (geometry)Internal medicineViral loadHuman immunodeficiency virus (HIV)Randomized controlled trialIntention-to-treat analysisImmunologyPhysicsOpticsHIV/AIDS drug development and treatmentHIV Research and TreatmentHIV/AIDS Research and Interventions
Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study | Litcius